{"id":2654,"date":"2018-06-01T16:04:10","date_gmt":"2018-06-01T14:04:10","guid":{"rendered":"https:\/\/www.rcts.fr\/uncategorized\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a"},"modified":"2020-04-07T16:01:11","modified_gmt":"2020-04-07T14:01:11","slug":"evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a","status":"publish","type":"post","link":"https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/","title":{"rendered":"\u00c9valuation de l\u2019impact du d\u00e9remboursement d\u2019une classe th\u00e9rapeutique sur le syst\u00e8me de sant\u00e9 fran\u00e7ais : l\u2019exemple des anti-arthrosiques symptomatiques d\u2019action lente (AASAL)"},"content":{"rendered":"<p>L\u2019objectif de l\u2019\u00e9tude \u00e9tait d\u2019investiguer les reports de prescriptions vers les antalgiques et les anti-inflammatoires non st\u00e9ro\u00efdiens (AINS) et d\u2019autres classes th\u00e9rapeutiques associ\u00e9es, en termes de volumes et de co\u00fbts, ainsi que les \u00e9ventuels \u00e9v\u00e9nements ind\u00e9sirables.<br \/>\n<a href=\"https:\/\/doi.org\/10.1016\/j.respe.2018.04.052\" rel=\"noopener noreferrer\" target=\"_blank\">Juin 2018 &#8211; Revue d&#8217;Epid\u00e9miologie et de Sant\u00e9 Publique<\/a><br \/>\n<strong>K. Mari,<\/strong> F. Guillemin, F. Rannou,  F. Mistretta, G. Badot, F. Gueyffier, M. Elegbe<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019objectif de l\u2019\u00e9tude \u00e9tait d\u2019investiguer les reports de prescriptions vers les antalgiques et les anti-inflammatoires non st\u00e9ro\u00efdiens (AINS) et d\u2019autres classes th\u00e9rapeutiques associ\u00e9es, en termes de volumes et de co\u00fbts, ainsi que les \u00e9ventuels \u00e9v\u00e9nements ind\u00e9sirables. Juin 2018 &#8211; Revue d&#8217;Epid\u00e9miologie et de Sant\u00e9 Publique K. Mari, F. Guillemin, F. Rannou, F. Mistretta, G. Badot, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false},"categories":[56],"class_list":["post-2654","post","type-post","status-publish","format-standard","hentry","category-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u00c9valuation de l\u2019impact du d\u00e9remboursement d\u2019une classe th\u00e9rapeutique sur le syst\u00e8me de sant\u00e9 fran\u00e7ais : l\u2019exemple des anti-arthrosiques symptomatiques d\u2019action lente (AASAL) - RCTs<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00c9valuation de l\u2019impact du d\u00e9remboursement d\u2019une classe th\u00e9rapeutique sur le syst\u00e8me de sant\u00e9 fran\u00e7ais : l\u2019exemple des anti-arthrosiques symptomatiques d\u2019action lente (AASAL) - RCTs\" \/>\n<meta property=\"og:description\" content=\"L\u2019objectif de l\u2019\u00e9tude \u00e9tait d\u2019investiguer les reports de prescriptions vers les antalgiques et les anti-inflammatoires non st\u00e9ro\u00efdiens (AINS) et d\u2019autres classes th\u00e9rapeutiques associ\u00e9es, en termes de volumes et de co\u00fbts, ainsi que les \u00e9ventuels \u00e9v\u00e9nements ind\u00e9sirables. Juin 2018 &#8211; Revue d&#8217;Epid\u00e9miologie et de Sant\u00e9 Publique K. Mari, F. Guillemin, F. Rannou, F. Mistretta, G. Badot, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/\" \/>\n<meta property=\"og:site_name\" content=\"RCTs\" \/>\n<meta property=\"article:published_time\" content=\"2018-06-01T14:04:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-07T14:01:11+00:00\" \/>\n<meta name=\"author\" content=\"Didier Not\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Didier Not\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\\\/\"},\"author\":{\"name\":\"Didier Not\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\"},\"headline\":\"\u00c9valuation de l\u2019impact du d\u00e9remboursement d\u2019une classe th\u00e9rapeutique sur le syst\u00e8me de sant\u00e9 fran\u00e7ais : l\u2019exemple des anti-arthrosiques symptomatiques d\u2019action lente (AASAL)\",\"datePublished\":\"2018-06-01T14:04:10+00:00\",\"dateModified\":\"2020-04-07T14:01:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\\\/\"},\"wordCount\":100,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\"},\"articleSection\":[\"Other\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\\\/\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\\\/\",\"name\":\"\u00c9valuation de l\u2019impact du d\u00e9remboursement d\u2019une classe th\u00e9rapeutique sur le syst\u00e8me de sant\u00e9 fran\u00e7ais : l\u2019exemple des anti-arthrosiques symptomatiques d\u2019action lente (AASAL) - RCTs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#website\"},\"datePublished\":\"2018-06-01T14:04:10+00:00\",\"dateModified\":\"2020-04-07T14:01:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rcts.fr\\\/en\\\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c9valuation de l\u2019impact du d\u00e9remboursement d\u2019une classe th\u00e9rapeutique sur le syst\u00e8me de sant\u00e9 fran\u00e7ais : l\u2019exemple des anti-arthrosiques symptomatiques d\u2019action lente (AASAL)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/\",\"name\":\"RCTs\",\"description\":\"Description\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rcts.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\",\"name\":\"RCTs\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"contentUrl\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"width\":163,\"height\":47,\"caption\":\"RCTs\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\",\"name\":\"Didier Not\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"caption\":\"Didier Not\"},\"url\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/author\\\/dnorcts-fr\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00c9valuation de l\u2019impact du d\u00e9remboursement d\u2019une classe th\u00e9rapeutique sur le syst\u00e8me de sant\u00e9 fran\u00e7ais : l\u2019exemple des anti-arthrosiques symptomatiques d\u2019action lente (AASAL) - RCTs","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/","og_locale":"en_US","og_type":"article","og_title":"\u00c9valuation de l\u2019impact du d\u00e9remboursement d\u2019une classe th\u00e9rapeutique sur le syst\u00e8me de sant\u00e9 fran\u00e7ais : l\u2019exemple des anti-arthrosiques symptomatiques d\u2019action lente (AASAL) - RCTs","og_description":"L\u2019objectif de l\u2019\u00e9tude \u00e9tait d\u2019investiguer les reports de prescriptions vers les antalgiques et les anti-inflammatoires non st\u00e9ro\u00efdiens (AINS) et d\u2019autres classes th\u00e9rapeutiques associ\u00e9es, en termes de volumes et de co\u00fbts, ainsi que les \u00e9ventuels \u00e9v\u00e9nements ind\u00e9sirables. Juin 2018 &#8211; Revue d&#8217;Epid\u00e9miologie et de Sant\u00e9 Publique K. Mari, F. Guillemin, F. Rannou, F. Mistretta, G. Badot, [&hellip;]","og_url":"https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/","og_site_name":"RCTs","article_published_time":"2018-06-01T14:04:10+00:00","article_modified_time":"2020-04-07T14:01:11+00:00","author":"Didier Not","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Didier Not"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/#article","isPartOf":{"@id":"https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/"},"author":{"name":"Didier Not","@id":"https:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5"},"headline":"\u00c9valuation de l\u2019impact du d\u00e9remboursement d\u2019une classe th\u00e9rapeutique sur le syst\u00e8me de sant\u00e9 fran\u00e7ais : l\u2019exemple des anti-arthrosiques symptomatiques d\u2019action lente (AASAL)","datePublished":"2018-06-01T14:04:10+00:00","dateModified":"2020-04-07T14:01:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/"},"wordCount":100,"commentCount":0,"publisher":{"@id":"https:\/\/www.rcts.fr\/#organization"},"articleSection":["Other"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/","url":"https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/","name":"\u00c9valuation de l\u2019impact du d\u00e9remboursement d\u2019une classe th\u00e9rapeutique sur le syst\u00e8me de sant\u00e9 fran\u00e7ais : l\u2019exemple des anti-arthrosiques symptomatiques d\u2019action lente (AASAL) - RCTs","isPartOf":{"@id":"https:\/\/www.rcts.fr\/#website"},"datePublished":"2018-06-01T14:04:10+00:00","dateModified":"2020-04-07T14:01:11+00:00","breadcrumb":{"@id":"https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.rcts.fr\/en\/evaluation-de-limpact-du-deremboursement-dune-classe-therapeutique-sur-le-systeme-de-sante-francais-lexemple-des-anti-arthrosiques-symptomatiques-daction-lente-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rcts.fr\/en\/"},{"@type":"ListItem","position":2,"name":"\u00c9valuation de l\u2019impact du d\u00e9remboursement d\u2019une classe th\u00e9rapeutique sur le syst\u00e8me de sant\u00e9 fran\u00e7ais : l\u2019exemple des anti-arthrosiques symptomatiques d\u2019action lente (AASAL)"}]},{"@type":"WebSite","@id":"https:\/\/www.rcts.fr\/#website","url":"https:\/\/www.rcts.fr\/","name":"RCTs","description":"Description","publisher":{"@id":"https:\/\/www.rcts.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rcts.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rcts.fr\/#organization","name":"RCTs","url":"https:\/\/www.rcts.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rcts.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","contentUrl":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","width":163,"height":47,"caption":"RCTs"},"image":{"@id":"https:\/\/www.rcts.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5","name":"Didier Not","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","caption":"Didier Not"},"url":"https:\/\/www.rcts.fr\/en\/author\/dnorcts-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/comments?post=2654"}],"version-history":[{"count":1,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2654\/revisions"}],"predecessor-version":[{"id":2656,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2654\/revisions\/2656"}],"wp:attachment":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/media?parent=2654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/categories?post=2654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}